A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone

Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spa...

Descripción completa

Detalles Bibliográficos
Autores: DENO Research Group, Calva, Carolina de la, Angulo Sánchez, Manuel, González Rojo, Paula, Peiró, Ana, Machado, Pau, Cebrián, Juan Luis, García Maroto, Roberto, Valcárcel, Antonio, Puertas García-Sandoval, Pablo, Valero Cifuentes, Gregorio, Pablos González, Óscar, Maireles Pérez, Míriam, Luisa Fontalva, María, Chaves, Iván, Orce, Aida, Coll Mesa, Luis, Pérez Muñoz, Israel, González Lizán, Fausto, Sanz, María del Carmen, Gracia Alegría, Isidro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/222103
Acceso en línea:https://hdl.handle.net/2445/222103
Access Level:acceso abierto
Palabra clave:Osteosarcoma
Tractament adjuvant del càncer
Adjuvant treatment of cancer
id ES_cb33d5e826e5b47c7da0ae2b8aa7fee8
oai_identifier_str oai:recercat.cat:2445/222103
network_acronym_str ES
network_name_str España
repository_id_str
spelling A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the BoneDENO Research GroupCalva, Carolina de laAngulo Sánchez, ManuelGonzález Rojo, PaulaPeiró, AnaMachado, PauCebrián, Juan LuisGarcía Maroto, RobertoValcárcel, AntonioPuertas García-Sandoval, PabloValero Cifuentes, GregorioPablos González, ÓscarMaireles Pérez, MíriamLuisa Fontalva, MaríaChaves, IvánOrce, AidaColl Mesa, LuisPérez Muñoz, IsraelGonzález Lizán, FaustoSanz, María del CarmenGracia Alegría, IsidroOsteosarcomaTractament adjuvant del càncerOsteosarcomaAdjuvant treatment of cancerBackground/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spain affiliated with the DENO Research Group. Seventy-three patients diagnosed with GCTB and treated with denosumab were included and stratified according to treatment strategy-neoadjuvant (n = 38), adjuvant (n = 8), and single treatment (n = 27). Results: Patients in the neoadjuvant group received denosumab for a median of 6.1 months, with reintroduction after surgery in 25.8% of all cases. Among the neoadjuvant patients treated with curettage, recurrence was 35.5%, with no association with denosumab treatment duration (p = 0.274) nor with denosumab reintroduction after surgery (p = 0.405). In the adjuvant group, those who completed treatment received denosumab for 15.3 months, while those still undergoing therapy received it for a median of 12.8 months; only one case (12.5%) recurred. Recurrence rates in neoadjuvant and adjuvant treatment strategies were not different (p = 0.394). Patients treated only with denosumab and no longer on treatment had received it for 34.2 months, with 31.3% recurrence; those still on treatment had received it for 51.8 months, with 25.0% recurrence. Across all strategies, more than 85% of patients reported favorable clinical outcomes, and only 43.8% presented adverse events. No deaths occurred during this study. Conclusions: Although patients who experienced recurrence during neoadjuvant treatment had longer durations of denosumab administration, the difference was not statistically significant. Similarly, recurrence rates did not differ significantly, whether denosumab was reintroduced after surgery or not. Among the patients treated with curettage, recurrence rates were comparable between neoadjuvant and adjuvant strategies. Discontinuation of the single treatment did not necessarily result in disease progression.MDPI2025202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion13 p.application/pdfhttps://hdl.handle.net/2445/222103Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/jcm14093242Journal of Clinical Medicine, 2025, vol. 14, num. 9, 3242https://doi.org/10.3390/jcm14093242cc-by (c) DENO Research Group et al., 2025http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2221032026-05-29T05:05:01Z
dc.title.none.fl_str_mv A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
title A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
spellingShingle A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
DENO Research Group
Osteosarcoma
Tractament adjuvant del càncer
Osteosarcoma
Adjuvant treatment of cancer
title_short A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
title_full A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
title_fullStr A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
title_full_unstemmed A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
title_sort A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
dc.creator.none.fl_str_mv DENO Research Group
Calva, Carolina de la
Angulo Sánchez, Manuel
González Rojo, Paula
Peiró, Ana
Machado, Pau
Cebrián, Juan Luis
García Maroto, Roberto
Valcárcel, Antonio
Puertas García-Sandoval, Pablo
Valero Cifuentes, Gregorio
Pablos González, Óscar
Maireles Pérez, Míriam
Luisa Fontalva, María
Chaves, Iván
Orce, Aida
Coll Mesa, Luis
Pérez Muñoz, Israel
González Lizán, Fausto
Sanz, María del Carmen
Gracia Alegría, Isidro
author DENO Research Group
author_facet DENO Research Group
Calva, Carolina de la
Angulo Sánchez, Manuel
González Rojo, Paula
Peiró, Ana
Machado, Pau
Cebrián, Juan Luis
García Maroto, Roberto
Valcárcel, Antonio
Puertas García-Sandoval, Pablo
Valero Cifuentes, Gregorio
Pablos González, Óscar
Maireles Pérez, Míriam
Luisa Fontalva, María
Chaves, Iván
Orce, Aida
Coll Mesa, Luis
Pérez Muñoz, Israel
González Lizán, Fausto
Sanz, María del Carmen
Gracia Alegría, Isidro
author_role author
author2 Calva, Carolina de la
Angulo Sánchez, Manuel
González Rojo, Paula
Peiró, Ana
Machado, Pau
Cebrián, Juan Luis
García Maroto, Roberto
Valcárcel, Antonio
Puertas García-Sandoval, Pablo
Valero Cifuentes, Gregorio
Pablos González, Óscar
Maireles Pérez, Míriam
Luisa Fontalva, María
Chaves, Iván
Orce, Aida
Coll Mesa, Luis
Pérez Muñoz, Israel
González Lizán, Fausto
Sanz, María del Carmen
Gracia Alegría, Isidro
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Osteosarcoma
Tractament adjuvant del càncer
Osteosarcoma
Adjuvant treatment of cancer
topic Osteosarcoma
Tractament adjuvant del càncer
Osteosarcoma
Adjuvant treatment of cancer
description Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spain affiliated with the DENO Research Group. Seventy-three patients diagnosed with GCTB and treated with denosumab were included and stratified according to treatment strategy-neoadjuvant (n = 38), adjuvant (n = 8), and single treatment (n = 27). Results: Patients in the neoadjuvant group received denosumab for a median of 6.1 months, with reintroduction after surgery in 25.8% of all cases. Among the neoadjuvant patients treated with curettage, recurrence was 35.5%, with no association with denosumab treatment duration (p = 0.274) nor with denosumab reintroduction after surgery (p = 0.405). In the adjuvant group, those who completed treatment received denosumab for 15.3 months, while those still undergoing therapy received it for a median of 12.8 months; only one case (12.5%) recurred. Recurrence rates in neoadjuvant and adjuvant treatment strategies were not different (p = 0.394). Patients treated only with denosumab and no longer on treatment had received it for 34.2 months, with 31.3% recurrence; those still on treatment had received it for 51.8 months, with 25.0% recurrence. Across all strategies, more than 85% of patients reported favorable clinical outcomes, and only 43.8% presented adverse events. No deaths occurred during this study. Conclusions: Although patients who experienced recurrence during neoadjuvant treatment had longer durations of denosumab administration, the difference was not statistically significant. Similarly, recurrence rates did not differ significantly, whether denosumab was reintroduced after surgery or not. Among the patients treated with curettage, recurrence rates were comparable between neoadjuvant and adjuvant strategies. Discontinuation of the single treatment did not necessarily result in disease progression.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/222103
url https://hdl.handle.net/2445/222103
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/jcm14093242
Journal of Clinical Medicine, 2025, vol. 14, num. 9, 3242
https://doi.org/10.3390/jcm14093242
dc.rights.none.fl_str_mv cc-by (c) DENO Research Group et al., 2025
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) DENO Research Group et al., 2025
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 13 p.
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419567741140992
score 15,812455

Similares en LA Referencia